Machine learning-based prediction of surgical benefit in borderline resectable and locally advanced pancreatic cancer

被引:0
|
作者
Zhang, Leiming [1 ,2 ]
Yu, Zehao [2 ]
Jin, Rong [1 ,2 ]
Yang, Xuanang [2 ]
Ying, Dongjian [1 ]
机构
[1] Ningbo Univ, Affiliated Lihuili Hosp, Dept Minimally Invas Surg, Ningbo, Zhejiang, Peoples R China
[2] Ningbo Univ, Hlth Sci Ctr, Ningbo, Zhejiang, Peoples R China
关键词
Machine learning; Borderline resectable pancreatic cancer; Locally advanced pancreatic cancer; Postoperative; Model prediction; DUCTAL ADENOCARCINOMA; SURGERY; 5-FLUOROURACIL; CHEMOTHERAPY; FOLFIRINOX; CONSENSUS; THERAPY;
D O I
10.1007/s00432-023-05071-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionSurgery represents a primary therapeutic approach for borderline resectable and locally advanced pancreatic cancer (BR/LAPC). However, BR/LAPC lesions exhibit high heterogeneity and not all BR/LAPC patients who undergo surgery can derive beneficial outcomes. The present study aims to employ machine learning (ML) algorithms to identify those who would obtain benefits from the primary tumor surgery.MethodsWe retrieved clinical data of patients with BR/LAPC from the Surveillance, Epidemiology, and End Results (SEER) database and classified them into surgery and non-surgery groups based on primary tumor surgery status. To eliminate confounding factors, propensity score matching (PSM) was employed. We hypothesized that patients who underwent surgery and had a longer median cancer-specific survival (CSS) than those who did not undergo surgery would certainly benefit from surgical intervention. Clinical and pathological features were utilized to construct six ML models, and model effectiveness was compared through measures such as the area under curve (AUC), calibration plots, and decision curve analysis (DCA). We selected the best-performing algorithm (i.e., XGBoost) to predict postoperative benefits. The SHapley Additive exPlanations (SHAP) approach was used to interpret the XGBoost model. Additionally, data from 53 Chinese patients prospectively collected was used for external validation of the model.ResultsAccording to the results of the tenfold cross-validation in the training cohort, the XGBoost model yielded the best performance (AUC = 0.823, 95%CI 0.707-0.938). The internal (74.3% accuracy) and external (84.3% accuracy) validation demonstrated the generalizability of the model. The SHAP analysis provided explanations independent of the model, highlighting important factors related to postoperative survival benefits in BR/LAPC, with age, chemotherapy, and radiation therapy being the top three important factors.ConclusionBy integrating of ML algorithms and clinical data, we have established a highly efficient model to facilitate clinical decision-making and assist clinicians in selecting the population that would benefit from surgery.
引用
收藏
页码:11857 / 11871
页数:15
相关论文
共 50 条
  • [11] Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
    Ferrone, Cristina R.
    Marchegiani, Giovanni
    Hong, Theodore S.
    Ryan, David P.
    Deshpande, Vikram
    McDonnell, Erin I.
    Sabbatino, Francesco
    Santos, Daniela Dias
    Allen, Jill N.
    Blaszkowsky, Lawrence S.
    Clark, Jeffrey W.
    Faris, Jason E.
    Goyal, Lipika
    Kwak, Eunice L.
    Murphy, Janet E.
    Ting, David T.
    Wo, Jennifer Y.
    Zhu, Andrew X.
    Warshaw, Andrew L.
    Lillemoe, Keith D.
    Fernandez-del Castillo, Carlos
    ANNALS OF SURGERY, 2015, 261 (01) : 12 - 17
  • [12] Surgical exploration with non-resection in the setting of resectable, borderline and locally advanced pancreatic cancer
    Soreide, Kjetil
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2022, 21 (03) : 205 - 206
  • [13] Predicting Surgical Margins in Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer Undergoing Resection
    Ren, Weizheng
    Xourafas, Dimitrios
    Ashley, Stanley W.
    Clancy, Thomas E.
    AMERICAN SURGEON, 2022, 88 (12) : 2899 - 2906
  • [14] Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer
    Mancini, Brandon R.
    Stein, Stacey
    Lloyd, Shane
    Rutter, Charles E.
    James, Edward
    Chang, Bryan W.
    Lacy, Jill
    Johung, Kimberly L.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 9 (06) : 982 - 988
  • [15] Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
    Roberto Alva-Ruiz
    Lavanya Yohanathan
    Jennifer A. Yonkus
    Amro M. Abdelrahman
    Lindsey A. Gregory
    Thorvadur R. Halfdanarson
    Amit Mahipal
    Robert R. McWilliams
    Wen Wee Ma
    Christopher L. Hallemeier
    Rondell P. Graham
    Travis E. Grotz
    Rory L. Smoot
    Sean P. Cleary
    David M. Nagorney
    Michael L. Kendrick
    Mark J. Truty
    Annals of Surgical Oncology, 2022, 29 : 1579 - 1591
  • [16] Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
    Alva-Ruiz, Roberto
    Yohanathan, Lavanya
    Yonkus, Jennifer A.
    Abdelrahman, Amro M.
    Gregory, Lindsey A.
    Halfdanarson, Thorvadur R.
    Mahipal, Amit
    McWilliams, Robert R.
    Ma, Wen Wee
    Hallemeier, Christopher L.
    Graham, Rondell P.
    Grotz, Travis E.
    Smoot, Rory L.
    Cleary, Sean P.
    Nagorney, David M.
    Kendrick, Michael L.
    Truty, Mark J.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (03) : 1579 - 1591
  • [17] Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer
    Shaib, Walid L.
    Ip, Andrew
    Cardona, Kenneth
    Alese, Olatunji B.
    Maithel, Shishir K.
    Kooby, David
    Landry, Jerome
    El-Rayes, Bassel F.
    ONCOLOGIST, 2016, 21 (02): : 178 - 187
  • [18] Treatment of pancreatic cancer-neoadjuvant treatment in borderline resectable/locally advanced pancreatic cancer
    Scheufele, Florian
    Hartmann, Daniel
    Friess, Helmut
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 4
  • [19] Effect of Radiotherapy in Neoadjuvant Treatment of Borderline Resectable and Locally Advanced Pancreatic Cancer
    Tang, Peng
    Zhang, Junfeng
    Zhou, Qiang
    Yi, Wenmin
    Wang, Huaizhi
    PANCREAS, 2025, 54 (03) : e246 - e254
  • [20] A Comparison of 3 Treatment Strategies for Locally Advanced and Borderline Resectable Pancreatic Cancer
    Lloyd, S.
    Chang, B. W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S89 - S89